Background
| The Oxford Medical Diagnostics team combines business acumen with scientific excellence. The business is centered on patents, proprietary know-how and the best academic researchers. Using the Company’s proprietary ‘CEAS’ and ‘PES’ technologies, the team is developing advanced methods of convenient, accurate and non-invasive methods of breath analysis targeted at the detection of metabolic and infectious diseases.
In addition, the Company offers its proprietary intellectual property and know-how to both clinical and industrial customers looking to exploit and develop the latest techniques in absorption, plasma emission and Ion Molecule Reaction – IMR – Mass Spectrometry. | |  |
Diabetes is a serious chronic illness that affects how the body uses food, and is a life threatening human disease if not treated. Currently, there is a significant inadequacy of diabetes testing methods. This is brought further into focus with data that illustrate that about 18.2 million Americans, 6.5% of the population, have diabetes and the number of diabetes cases in the United States is increasing at about 5 percent each year.
Importantly, therefore, clinicians have welcomed the concept of a definitive, quantitative, non-invasive and cost effective breath diagnostics technology.
Oxford Medical Diagnostics Limited was formed during the summer of 2010 as a merger of three entities: EV (Medical Screening); Oxford Medical Diagnostics; and the technology and expertise in laser and Broadband Cavity Enhanced Absorption Spectroscopy (BBCEAS) available in the University of Oxford.
With this unrivalled research and development capability, the Company is able to provide product and development solutions across a wide spectrum of both clinical and industrial applications.